LETFIT 2.5 MG

Non-steroidal aromatase inhibitor that significantly reduces estrogen production and is used in hormone-sensitive breast cancer.

Letfit 2.5 mg is a brand name for oral letrozole. It is a non-steroidal aromatase inhibitor primarily prescribed for postmenopausal women with hormone-sensitive conditions.

Primary Uses & Indications

1. Hormone Receptor-Positive Breast Cancer: Used as a primary or secondary (adjuvant) treatment in postmenopausal women to reduce the risk of cancer recurrence or manage advanced stage progression.
2. Off-Label Ovulation Induction: Frequently prescribed by fertility specialists off-label to induce ovulation in women with polycystic ovary syndrome (PCOS) or unexplained infertility.

Letfit 2.5 mg (active pharmaceutical ingredient: Letrozole 2.5 mg) is a potent non-steroidal aromatase inhibitor. Manufactured primarily in South Asia (including India by pharmaceutical brands like POWERBOLI LAB, its active ingredient Letrozole is regulated and prescribed across different countries for specific medical conditions, as well as used off-label in fertility and sports medicine.

1. Primary Approved Medical Uses (Worldwide)

In almost all major international health jurisdictions (including the US FDA, UK MHRA, EMA in Europe, and CDSCO in India), Letrozole 2.5 mg is officially indicated for:

1. Hormone Receptor-Positive (HR+) Breast Cancer: Prescribed as first-line treatment for postmenopausal women with early-stage, locally advanced, or metastatic breast cancer.
2. Adjuvant & Sequential Therapy: Used following surgery (adjuvant) or after 5 years of Tamoxifen therapy (extended adjuvant) to reduce the risk of cancer recurrence.
3. Mechanism: It selectively blocks the aromatase enzyme, which converts androgens into estrogens. By reducing circulating estrogen levels by up to 98-99%, it starves estrogen-dependent tumor cells and inhibits their growth.

2. Country-Wise Regulatory & Clinical Overview

India & South Asia (Country of Origin)

1. Status: Sold under brand names like Letfit 2.5 mg, Femara, and generic Letrozole 2.5 mg.
2. Medical Practice: In addition to oncology, Indian reproductive medicine guidelines extensively approve and utilize Letrozole 2.5 mg as a first-line ovulation induction agent for women with Polycystic Ovary Syndrome (PCOS) undergoing fertility treatment.

United States & Canada

1. Brand Equivalence: Known under the brand Femara (Novartis) or generic Letrozole 2.5 mg.
2. FDA Status: Approved strictly for postmenopausal breast cancer.

United Kingdom, European Union & Australia

1. Regulatory Oversight: Approved by the EMA, UK MHRA, and TGA.
2. Indication: Adjuvant and first-line treatment of postmenopausal hormone-dependent advanced breast cancer.
3. Fertility Guidelines: Recognized by various European fertility societies for fertility treatment under specialized clinical supervision.